Response to comments on “Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan”
- DOI
- 10.1007/s12185-026-04253-8
- Published
- 2026-07-14
- Container
- International Journal of Hematology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s12185-026-04253-8,
title = {Response to comments on “Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan”},
author = {Hirotaka Matsui and Jun Takizawa and Kensuke Kojima and Tetsuzo Tauchi and Chiaki Ikeda and Yu Aruga and Hiroki Sakamoto and Risa Takenaka and Jinhaeng Park and Tetsuo Morita and Hiromichi Matsushita and Ritsuro Suzuki},
year = {2026},
journal = {International Journal of Hematology},
doi = {10.1007/s12185-026-04253-8},
url = {https://doi.org/10.1007/s12185-026-04253-8}
}RIS
TY - JOUR TI - Response to comments on “Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan” AU - Hirotaka Matsui AU - Jun Takizawa AU - Kensuke Kojima AU - Tetsuzo Tauchi AU - Chiaki Ikeda AU - Yu Aruga AU - Hiroki Sakamoto AU - Risa Takenaka AU - Jinhaeng Park AU - Tetsuo Morita AU - Hiromichi Matsushita AU - Ritsuro Suzuki PY - 2026 JO - International Journal of Hematology DO - 10.1007/s12185-026-04253-8 UR - https://doi.org/10.1007/s12185-026-04253-8 ER -
APA
Matsui, H., Takizawa, J., Kojima, K., Tauchi, T., Ikeda, C., Aruga, Y., Sakamoto, H., Takenaka, R., Park, J., Morita, T., Matsushita, H., & Suzuki, R. (2026). Response to comments on “Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan”. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04253-8
Source records
- crossref · retrieved 2026-09-26T06:47:24.426Z